{"title": "U.S. FDA approves UCB's new epilepsy treatment, BRIVIACT\u00ae, for patients with partial-onset seizures", "author": "Varun Saxena", "url": "https://www.fiercepharma.com/drug-delivery/u-s-fda-approves-ucb-s-new-epilepsy-treatment-briviact%C2%AE-for-patients-partial-onset", "hostname": "fiercepharma.com", "description": "- BRIVIACT\u00ae (brivaracetam), a new molecular entity, is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy(1) - The... | - BRIVIACT\u00ae (brivaracetam), a new molecular entity, is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy(1) - The...", "sitename": "FiercePharma", "date": "2016-02-22", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}